These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31570466)

  • 21. The Predictive Value of Pretreatment Neutrophil-To-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma.
    Chen MF; Chen PT; Kuan FC; Chen WC
    Ann Surg Oncol; 2019 Jan; 26(1):190-199. PubMed ID: 30362062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Hirasawa Y; Kubota Y; Mura E; Suzuki R; Tsurui T; Iriguchi N; Ishiguro T; Ohkuma R; Shimokawa M; Ariizumi H; Horiike A; Wada S; Ariyoshi T; Goto S; Otsuka K; Murakami M; Kiuchi Y; Yoshimura K; Hoffman RM; Tsunoda T
    Anticancer Res; 2024 Aug; 44(8):3397-3407. PubMed ID: 39060084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: Neutrophil lymphocyte ratio/prealbumin ratio.
    Lv Y; Zhang J; Liu Z; Tian Y; Liu F
    Medicine (Baltimore); 2019 Feb; 98(7):e14562. PubMed ID: 30762804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Preoperative Neutrophil-To-Lymphocyte Ratio Is a Novel Immune Parameter for the Prognosis of Esophageal Basaloid Squamous Cell Carcinoma.
    Xiao Q; Zhang B; Deng X; Wu J; Wang H; Wang Y; Wang W
    PLoS One; 2016; 11(12):e0168299. PubMed ID: 27959959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
    Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
    Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma.
    Han LH; Jia YB; Song QX; Wang JB; Wang NN; Cheng YF
    Asian Pac J Cancer Prev; 2015; 16(6):2245-50. PubMed ID: 25824745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-dimer levels predict the treatment efficacy and prognosis of esophageal squamous cell carcinoma treated with PD-1/PD-L1 inhibitors.
    Wu Y; Liu X; Li H; Wang W; Ye L; Zhou Y; Chen D
    Int J Biol Markers; 2024 Sep; 39(3):209-216. PubMed ID: 38887052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients.
    Li H; Li B; Wang X; Zhang H; Wang C; Fan B; Wang L
    Nutrition; 2024 Aug; 124():112462. PubMed ID: 38663128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Significance of Low Body Mass Index and Betel-Quid Use in the 5-Year Survival Rates of Esophageal Squamous Cell Carcinoma Patients.
    Pan YP; Hsu TY; Lin JY; Ho CJ; Kuan CY; Chou WC; Lai CH; Chang PH; Yeh KY
    Nutr Cancer; 2018; 70(8):1315-1321. PubMed ID: 30900908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites.
    Guo JC; Lin CY; Lin CC; Huang TC; Lien MY; Lu LC; Kuo HY; Hsu CH
    Oncology; 2021; 99(10):652-658. PubMed ID: 34340231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated preoperative neutrophil-to-lymphocytes ratio predicts poor prognosis after esophagectomy in T1 esophageal cancer.
    Nakamura K; Yoshida N; Baba Y; Kosumi K; Uchihara T; Kiyozumi Y; Ohuchi M; Ishimoto T; Iwatsuki M; Sakamoto Y; Watanabe M; Baba H
    Int J Clin Oncol; 2017 Jun; 22(3):469-475. PubMed ID: 28097441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma.
    Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
    Anticancer Res; 2022 Mar; 42(3):1499-1507. PubMed ID: 35220245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
    Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
    Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prognostic influence of preoperative Nutritional Risk Screening -2002 (NRS-2002) score for patients with thoracic esophageal squamous cell carcinoma receiving surgery].
    Sun HJ; Guo XW; Ji SJ; Zhou SB; Gu L
    Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):917-921. PubMed ID: 30605983
    [No Abstract]   [Full Text] [Related]  

  • 36. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
    Jin Z; Cao Y; Lu Z; Liu C; Shen L
    Int Immunopharmacol; 2024 Aug; 137():112364. PubMed ID: 38865752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
    Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
    Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients.
    Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Kurashige J; Hiyoshi Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Surg Today; 2016 Apr; 46(4):405-13. PubMed ID: 26036223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative NLR and PLR in the middle or lower ESCC patients with radical operation.
    He YF; Luo HQ; Wang W; Chen J; Yao YW; Yan Y; Wu SS; Hu XX; Ke LH; Niu JY; Li HM; Ji CS; Hu B
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26947428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
    Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
    Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.